BioNTech’s Big Cancer Drug Move

BioNTech is making waves again—this time, they’re prepping to file for approval of their first cancer drug, BNT323, by the end of 2024. But with all the tariff drama and global supply chain jitters, they’re not taking any chances: BioNTech’s diversifying its suppliers so they’re not just relying on China. Plus, they’re sitting on a massive cash pile from their COVID-19 vaccine days, fueling even more cancer research. New CFO incoming, too! #BioNTech #CancerResearch #PharmaNews #DrugApproval #Biotech #Health